Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.44 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.44 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | CCR5 | P51681 | 3/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629845 | 0.88 | PTPN1 (0.46) | PTPN1SLC6A4USP28USP25PTP4A3 | |
| SCHEMBL3006427 | 0.88 | PTPN1 (0.46) | PTPN1SLC6A4USP28USP25PTP4A3 | |
| SCHEMBL4646906 | 0.86 | PTPN1 (0.53) | PTPN1SLC6A4SMN1; SMN2RAB9APTPN2 | |
| SCHEMBL4646378 | 0.84 | PTPN1 (0.51) | PTPN1PTGER1CYP1A2PTPN2 | |
| SCHEMBL4647040 | 0.84 | PTPN1 (0.50) | PTPN1SLC6A4ALDH1A1SMN1; SMN2 | |
| Potassium SCHEMBL4647048 | 0.84 | PTPN1 (0.50) | PTPN1SLC6A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL3006552 | 0.83 | PTPN1 (0.44) | PTPN1SLC6A4PTP4A3CCR5PTGER1 | |
| SCHEMBL4643501 | 0.82 | PTPN1 (0.62) | PTPN1SLC6A4PTP4A3 | |
| SCHEMBL4646366 | 0.81 | PTPN1 (0.61) | PTPN1SLC6A4PTP4A3 | |
| SCHEMBL630221 | 0.81 | PTPN1 (0.49) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293782-A1 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1960377-A1 | l , l , 3-TRI0X0-l , 2 , 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS | Novartis AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007067614-A1 | l, l, 3-TRI0X0-l, 2, 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293782-A1 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors | PTPRS, IRS1, PTPMT1 | PTPN1 10/4885SLC6A4 3509/4885USP28 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.